WASHINGTON, D.C.—Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in a head-to-head study aimed at bringing the implant to the U.S.—but the company believes it has a ...
Boston Scientific, Inc. BSX has obtained a CE Mark for the ACURATE Prime Aortic Valve System — the newest transcatheter aortic valve replacement (TAVR) technology in its structural heart portfolio.
Boston Scientific Corporation (NYSE:BSX) is pulling the plug on its ACURATE neo2 and Prime aortic valve systems. What Happened: The medical technology giant halted global sales and abandoned ...
MARLBOROUGH, Mass., Aug. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results